Literature DB >> 17823804

[Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction].

B Wabbels1, M Förl.   

Abstract

After proximal facial nerve lesions, misrouting of nerve fibres may cause the phenomenon of crocodile tears. Transconjunctival injections of botulinum toxin in the palpebral part of the lacrimal gland are the treatment of choice. An initial dose of 2.5 U of toxin is recommended, and injections may be repeated after 6 months if symptoms reoccur. Botulinum toxin A is also a highly effective temporary treatment for involutional (spasmodic) entropion until surgery is performed. A dose of 10 U of botulinum toxin is injected in the pretarsal part of the lower lid near the eyelashes. Botulinum toxin treatment is also effective for dysthyroid upper eye lid retraction, especially in instable thyroid disease or mild retraction. Slight transient ptosis may occur in some cases. Depending on the amount of retraction, a dose of 5 or 7.5 U of toxin is injected into the subconjunctival space at the superior margin of the tarsal plate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17823804     DOI: 10.1007/s00347-007-1592-z

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.174


  26 in total

1.  Thyroid associated ophthalmopathy: botulinum toxin A in the treatment of upper eyelid retraction--a pilot study.

Authors:  F Träisk; L Tallstedt
Journal:  Acta Ophthalmol Scand       Date:  2001-12

Review 2.  Long term efficacy and safety of botulinum toxin A injection for crocodile tears syndrome.

Authors:  D E Barañano; N R Miller
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

3.  Chemodenervation in treatment of upper eyelid retraction.

Authors:  S B Ozkan; D Can; M F Söylev; A K Arsan; S Duman
Journal:  Ophthalmologica       Date:  1997       Impact factor: 3.250

4.  Botulinum toxin A induced protective ptosis.

Authors:  G G Adams; C M Kirkness; J P Lee
Journal:  Eye (Lond)       Date:  1987       Impact factor: 3.775

5.  Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion.

Authors:  J Carruthers; H A Stubbs
Journal:  Can J Neurol Sci       Date:  1987-02       Impact factor: 2.104

6.  Injection treatment of endocrine orbital myopathy.

Authors:  A B Scott
Journal:  Doc Ophthalmol       Date:  1984-08-15       Impact factor: 2.379

7.  Botulinum toxin for the temporary treatment of involutional lower lid entropion: a clinical and morphological study.

Authors:  D H Steel; H B Hoh; R A Harrad; C R Collins
Journal:  Eye (Lond)       Date:  1997       Impact factor: 3.775

8.  Botulinum toxin type A in upper lid retraction of Graves' ophthalmopathy.

Authors:  R Ebner
Journal:  J Clin Neuroophthalmol       Date:  1993-12

9.  Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy.

Authors:  B Boroojerdi; A Ferbert; M Schwarz; H Herath; J Noth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

10.  Botulinum toxin type a for dysthyroid upper eyelid retraction.

Authors:  K E Morgenstern; J Evanchan; J A Foster; K V Cahill; J A Burns; D E E Holck; J D Perry; A E Wulc
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2004-05       Impact factor: 1.746

View more
  9 in total

1.  [Surgical management of entropion].

Authors:  K Wozniak; F Sommer
Journal:  Ophthalmologe       Date:  2010-10       Impact factor: 1.059

2.  [Drug therapy and radiotherapy in Graves' orbitopathy].

Authors:  F Beisse; W A Lagrèze; M Schmucker
Journal:  Ophthalmologe       Date:  2011-05       Impact factor: 1.059

3.  Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.

Authors:  Dirk Dressler
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

4.  [Graves' ophthalmopathy].

Authors:  A Eckstein; J Esser
Journal:  Internist (Berl)       Date:  2010-05       Impact factor: 0.743

Review 5.  [Graves' ophthalmopathy].

Authors:  A Eckstein; D Dekowski; D Führer-Sakel; U Berchner-Pfannschmidt; J Esser
Journal:  Ophthalmologe       Date:  2016-04       Impact factor: 1.059

Review 6.  [Use of botulinum toxin in strabismus].

Authors:  B Wabbels
Journal:  Ophthalmologe       Date:  2016-07       Impact factor: 1.059

7.  [Botulinum toxin for the treatment of spastic entropion. Case report].

Authors:  J Winterhoff; S Köhler; R Laskawi
Journal:  HNO       Date:  2013-07       Impact factor: 1.284

8.  [Update on endocrine orbitopathy].

Authors:  A Eckstein; U Berchner-Pfannschmidt; D Führer; J Esser
Journal:  Ophthalmologe       Date:  2013-11       Impact factor: 1.059

Review 9.  Use of Botulinum Neurotoxin in Ophthalmology.

Authors:  Emel Başar; Ceyhun Arıcı
Journal:  Turk J Ophthalmol       Date:  2016-12-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.